“I’m thrilled to partner with BridgeBio and this stellar investor syndicate to advance BBOT’s unique portfolio of precision oncology assets targeting RAS-driven cancers,” said lead investor Raymond Kelleher, MD, PhD, of Cormorant Asset Management. “BBOT’s innovative chemical biology approaches to inhibit a wide spectrum of KRAS mutations in both the “on” and “off” states, as well as bypass mechanisms exploiting PI3K signaling, promise to transform the treatment of this important class of cancers.”